BioMarin (BMRN) | Stock Overview & Key Data
BioMarin Performance Comparison
Stock Range
Today's Range
Low: $57.74
High: $58.85
on August 22, 2025
52 Week Range
Low: $52.93
High: $93.04
on April 9, 2025
on August 29, 2024
All-Time High: $151.75 on July 20, 2015
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$11.2B
EPS
3.39
P/E Ratio (TTM)
17.13
Forward P/E
19.42
P/B Ratio
1.85
PEG Ratio
0.14
Div. Yield
N/A
ROE
11.62%
Beta
0.181
Debt to Equity
10.02
Financial Highlights
Profitability
Gross Margin
81.82%
Operating Margin
33.55%
Profit Margin
21.45%
Returns and Earnings
Return on Assets (TTM)
7.50%
Return on Equity (TTM)
11.62%
EBITDA
$934.0M
Net Income (TTM)
$657.2M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$16.06
Quarterly Revenue Growth (YoY)
15.90%
Quarterly Earnings Growth (YoY)
124.40%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| BioMarin BMRN | 11.15B Large-cap | 1.81% | -1.05% | 0.98% | -15.11% | -11.90% | -34.96% | -35.67% | -23.34% |
| Vertex VRTX | 100.19B Large-cap | 0.62% | -15.94% | -8.94% | -17.95% | -2.60% | -17.90% | 40.27% | 46.36% |
| Regeneron REGN | 62.88B Large-cap | 1.56% | 5.09% | -1.23% | -17.35% | -17.58% | -50.84% | -1.12% | -2.18% |
| Alnylam ALNY | 60.95B Large-cap | 1.22% | 39.69% | 57.22% | 82.53% | 94.50% | 66.67% | 115.42% | 245.80% |
| Insmed INSM | 28.03B Large-cap | 3.19% | 28.14% | 99.33% | 64.79% | 88.53% | 67.28% | 438.29% | 358.23% |
| Royalty Pharma plc RPRX | 20.90B Large-cap | -0.03% | 0.66% | 12.47% | 7.51% | 40.91% | 28.84% | -15.63% | -13.67% |
Ownership & Short Interest
Insider Ownership
0.78%
Institutional Ownership
98.69%
Shares Short
5M
Short Ratio
2.84
Short % of Shares Outstanding
3.44%
Average 10-Day Volume
2M
Average 90-Day Volume
2M
BioMarin Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in BioMarin would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is BMRN's 52-week high and low?
- In the last 52 weeks, BioMarin reached a high of $93.04 (on August 29, 2024) and a low of $52.93 (on April 9, 2025).
- What is the market cap and P/E ratio for BMRN?
- Curious about BioMarin's size and valuation? Its market capitalization stands at 11.15B. When it comes to valuation, the P/E ratio (trailing twelve months) is 17.13, and the forward P/E (looking ahead) is 19.42.
- Does BMRN pay dividends? If so, what's the yield?
- As for dividends, BioMarin isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are BioMarin's main competitors or similar companies to consider before investing?
When looking at BioMarin, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX100.19B Healthcare Biotechnology -17.90% 40.27% Regeneron
REGN62.88B Healthcare Biotechnology -50.84% -1.12% Alnylam
ALNY60.95B Healthcare Biotechnology 66.67% 115.42% Insmed
INSM28.03B Healthcare Biotechnology 67.28% 438.29% Royalty Pharma plc
RPRX20.90B Healthcare Biotechnology 28.84% -15.63% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for BioMarin Pharmaceutical Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of BioMarin's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 11.62%, the Debt to Equity ratio from the most recent quarter is 10.02, and its Gross Profit Margin stands at 81.82%.
- What is the recent revenue and earnings growth for BMRN?
- Looking at BioMarin's growth, its revenue over the trailing twelve months (TTM) was $3B. Compared to the same quarter last year (YoY), quarterly revenue grew by 15.90%, and quarterly earnings saw a YoY growth of 124.40%.
- How much of BMRN stock is held by insiders and institutions?
- Wondering who owns BioMarin stock? Company insiders (like executives and directors) hold about 0.78% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 98.69%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.